<DOC>
	<DOCNO>NCT02213068</DOCNO>
	<brief_summary>This study do investigate impact change immunosuppressive medication tacrolimus ( Prograf® ) belatacept ( Nulojix® ) three ( 3 ) six ( 6 ) month kidney transplantation . The immune system body 's defense infection disease . After transplantation , body see new organ `` foreign '' try destroy `` reject '' . Immunosuppressive medication help prevent immune system attack transplant organ . The primary purpose research study evaluate effect three ( 3 ) different immunosuppressive treatment rejection post-transplant kidney recipient . This study test whether switch tacrolimus belatacept improve long-term kidney function . Three immunosuppressant use study- mycophenolic acid ( MPA ) , mycophenolate mofetil ( MMF ) tacrolimus- medication approve United States Food Drug Administration ( FDA ) use transplant . All medication routinely use kidney recipient Northwestern University . Belatacept ( `` study drug '' ) approve FDA use time transplant . However , use belatacept study consider investigational FDA approve use begin 3 month transplant . This study involve 51 adult kidney transplant recipient Northwestern .</brief_summary>
	<brief_title>Belatacept 3 Month Post Transplant Conversion Study</brief_title>
	<detailed_description>Immunosuppressive therapy calcineurin inhibitor ( CNI ) cyclosporine ( CsA ) Tacrolimus ( Tac ) , radically change field organ transplantation . Ironically , although extensively effectively use kidney transplantation solid organ transplant , CsA Tac cause important adverse renal side effect : acute chronic renal dysfunction , hemolytic-uremic syndrome , hypertension , electrolyte disturbance tubular acidosis . Chronic nephrotoxicity CNI implicate principal cause post-transplant renal dysfunction characterize irreversible progressive tubular atrophy , interstitial fibrosis , focal hyalinosis small renal artery arteriole . Attempts minimize CNIs known toxicity marginally successful due unacceptable rate acute rejection drug toxicity . Patients convert alternative immunosuppressive therapy relate CNI side effect include neurotoxicity , nephrotoxicity , cardiovascular ( HTN , hyperlipidemia ) , metabolic ( NODAT ) , cosmetic side effect . Furthermore , class medication associate also , block Interleukin 2 ( IL2 ) production , negative impact regulatory T cell ( Tregs ) generation ( important subpopulation T helper cell associate positive immunomodulation donor specific hypo-responsiveness ) . Until approval Belatacept adult EBV+ renal transplant recipient , limited alternative immunosuppressive agent available mitigate drug induce renal impairment . The phase III drug trial Belatacept combination MMF corticosteroid result significant sustained improvement glomerular filtration rate ( GFR ) one year three year post transplant . The overall safety belatacept compare cyclosporine de novo transplant recipient similar . However , increased rate severity early acute rejection post-transplant lymphoproliferative disorder ( PTLD ) central nervous system patient treat belatacept . In phase II switch study conduct Bristol Myers Squibb ( BMS ) , incidence acute rejection 24 month post conversion similar patient remain CNI ( 4 % ) compare convert belatacept ( 7 % ) . There reported case post-transplant lymphoproliferative disorder ( PTLD ) patient population two year post randomization . However , one belatacept patient Mexico develop tuberculosis non-serious fungal infection belatacept treated patient . Mechanistically , CD28 ( Cluster Differentiation 28 ) CTLA-4 ( cytotoxic T-lymphocyte-associated protein 4 ) important function regulatory T cell ( Tregs ) . Belatacept bind CD80/CD86 ( Cluster Differentiation 80/Cluster Differentiation 86 ) ligands antigen present cell ( APCs ) prevent CD28 bind ligands deliver costimulatory signal activate T Cell . CTLA-4 related receptor express activated T cell also recognize CD80/CD86 ( Cluster Differentiation 80/Cluster Differentiation 86 ) thus term co-inhibitory . It transmit cell intrinsic cell extrinsic negative signal impair activation . Investigation effect early conversion Belatacept month 3 post-transplant subpopulation T cell B cell peripheral blood allograft biopsy-derived gene expression subpopulation profile plan . Optimization Belatacept immunosuppressive regimen achieve good long term renal function improve graft survival require understanding relationship cell population clinical outcome .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion Criteria 1 . Adult ≥ 18 year age 2 . Male Female 3 . EBV seropositive 4 . Recipient renal transplant living decease donor Exclusion Criteria 1 . Recipients EBV serostatus negative unknown 2 . History acute rejection ( AR ) within 3 month prior randomization 3 . History positive donor specific antibody ( DSA ) 4 . History antibody mediate rejection 5 . Positive Tcell lymphocytotoxic cross match 6 . Proteinuria &gt; 1 g/day &gt; 0.5 g/day diabetic 7 . Rejection 3 month posttransplant screen biopsy 8 . BK nephropathy 3 month posttransplant screen biopsy 9 . Positive pregnancy test time randomization female child bear potential 10 . History previous transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Kidney</keyword>
	<keyword>Renal</keyword>
	<keyword>Transplant</keyword>
	<keyword>EBV</keyword>
	<keyword>Immunosuppressants</keyword>
	<keyword>Belatacept</keyword>
</DOC>